Abstract
During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic.
All Keywords
【저자키워드】 COVID-19, Treatment, Remdesivir, clinical trials, 【초록키워드】 clinical trial, COVID-19 pandemic, drugs, Intervention, Outbreaks, Premature, disease, Evidence, effort, identify, curative, 【제목키워드】 Trial,
【저자키워드】 COVID-19, Treatment, Remdesivir, clinical trials, 【초록키워드】 clinical trial, COVID-19 pandemic, drugs, Intervention, Outbreaks, Premature, disease, Evidence, effort, identify, curative, 【제목키워드】 Trial,